ATG9A and neoplasm: To date, only seven out of the 80 patients from our cohort presented a cancer recurrence, and amongst them, five presented an increase in ATG9A mRNA levels in tumor cells compared to the healthy adjacent tissues (3/5 patients were diagnosed with TN, and 2/5 with Luminal B).